AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
17 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
18 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
19 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
20 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
21 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
22 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
23 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
24 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
25 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
26 Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Serum-free light chains (sFLCs) are markers for diagnosis and response assessment in multiple myeloma. Under International Myeloma Working Group (IMWG) criteria, a ≥25% increase from nadir in involved minus uninvolved sFLC, with an absolute increase of ≥10 mg/dL, defines disease progression (PD) in patients without measurable serum or urine M-protein. In measurable M-protein disease, the same signal before IMWG-PD is termed free light chain escape (FLCe) and may mark early progression. We updated the cohort to evaluate FLCe features, prognosis, and early intervention.
Methods: Our institutional database included 3,050 patients with multiple myeloma, including 2,170 admitted from September 2018 to September 2025 and 1,338 with newly diagnosed multiple myeloma (NDMM). The analysis included 278 NDMM patients with measurable serum and/or urine M-protein, FLCe and/or IMWG-PD, and complete serial SPEP, UPEP, SIFE, UIFE, and sFLC monitoring. Response and progression were assessed by IMWG criteria. Follow-up was updated through July 14, 2026. Endpoints included FLCe-free survival (ePFS, treatment initiation to FLCe), PFS, second time to progression or FLCe (2nd TTPe, first PD or FLCe to subsequent PD, FLCe, or death), and OS.
Results: Among 278 patients, 39 (14.0%) developed FLCe (FLCe group), and 239 (86.0%) developed PD without FLCe (PD-only group). Of the 39 FLCe patients, 10 received early intervention after FLCe onset (early-intervention FLCe group), 26 progressed to PD before treatment adjustment (FLCe-to-PD group), and 3 were lost to follow-up. Median follow-up was 44.77 months (95% CI, 40.9-48.2). Compared with PD-only, FLCe was associated with more severe baseline end-organ damage: anemia (66.67% vs 48.95%, P=0.040), hypoalbuminemia (58.97% vs 38.91%, P=0.018), renal impairment (20.51% vs 8.79%, P=0.043), elevated β2MG (82.05% vs 62.34%, P=0.017), and bone disease (89.74% vs 51.88%, P<0.001). FLCe was associated with higher DS III (97.44% vs 69.87%, P<0.001), ISS III (64.10% vs 35.98%, P<0.001), and R-ISS III disease (46.15% vs 22.18%, P<0.001), higher baseline urine M-protein, rFLC, and dFLC, and more frequent del(13q) (74.36% vs 51.26%, P=0.012), del(17p) (28.21% vs 13.81%, P=0.041), and 1q21+ (56.41% vs 34.31%, P=0.014). High-risk cytogenetics by R-ISS (48.72% vs 27.62%, P=0.014) and IMS-IMWG criteria (48.72% vs 20.25%, P<0.001) were more common.
In the institutional database, OS and PFS analyses were available for 1,579 and 1,604 patients. Median OS was 77.7 months (95% CI, 71.5-not reached), and median PFS was 39.0 months (95% CI, 35.7-41.7). Median ePFS in FLCe was shorter than median PFS in PD-only (8.3 months [95% CI, 7.2-14.4] vs 21.8 months [95% CI, 17.8-23.7], P=0.0027). In FLCe-to-PD, the median interval from FLCe to IMWG-PD was 4.88 months (95% CI, 2.57-7.73), and median PFS was shorter than in PD-only (12.8 months [95% CI, 10.2-21.0] vs 21.8 months [95% CI, 17.8-23.7], P=0.0338). Thus, patients without timely intervention after FLCe reached IMWG-PD earlier and may represent a higher-risk subgroup.
No second progression or death occurred in early-intervention FLCe. The 24-month second-progression rates were 51.4% in FLCe-to-PD and 60.1% in PD-only; 24-month mortality rates were 18.3% and 6.0%. OS differed across the three groups (global log-rank P=0.02), and median OS was not reached. OS was longer in early-intervention FLCe than in FLCe-to-PD (P=0.042), whereas FLCe-to-PD had shorter OS than PD-only (P=0.018). FLCe remained independently associated with inferior OS (HR 3.085, 95% CI 1.321-7.206, P=0.00925). Early-intervention FLCe showed longer 2nd TTPe than PD-only (P=0.044). The three-group global log-rank comparison was not significant (P=0.097), possibly due partly to small subgroup size, but Kaplan-Meier curves showed sustained disease control after early intervention.
Conclusion: FLCe was associated with more severe end-organ damage, higher DS, ISS, and R-ISS stages, high-risk cytogenetics, and elevated baseline dFLC/rFLC. Median ePFS was 8.3 months, and the median interval from FLCe to clinical PD was 4.88 months. FLCe was independently associated with inferior OS. Early treatment adjustment after FLCe correlated with improved survival, whereas delay until IMWG-PD showed poorer prognosis. These findings support FLCe as a potential preclinical marker in myeloma patients with measurable M-protein. Timely adjustment after FLCe may improve disease control and prognosis.